NCT05513742Phase 2Completed

A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-05-15Actual

Enrollment · participants49Actual

Source updated2026-09-25Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-05-06 · 1 field changed

Primary completion date changed

− Before

~~28 Apr 2025~~

+ After

15 May 2025

Check registry source

Study details

Conditions studied

Metastatic Colorectal Cancer; Colon Cancer; Rectal Cancer

Treatments or interventions studied

CTX-009Drug

Primary outcomes · main study measures

Read the study measures

measure: Overall Response Rate; description: Percentage of patients whose best overall response is assessed as complete response (CR) or partial response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions.; timeFrame: From first dose of CTX-009 until treatment discontinuation (an average of 16 weeks)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history